Take TrialScope’s Trial Disclosure Survey
Leader in clinical trial solutions continues to deliver innovative resources for sponsors to measure disclosure
Jersey City, NJ – TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced the release of its second Clinical Trial Disclosure Maturity Survey for clinical trial sponsors to perform self-assessments of their disclosure practices.
The measurement tool, launched in 2015, tracks clinical trial disclosure trends, clinical trial requirements and trial sponsors’ current practices from across the life sciences industry. The assessment is designed to allow sponsors to identify their organization’s capabilities, recognize best practices and benchmark their capabilities against their peers.
Clinical trial sponsors seeking to participate in the 2017 Clinical Trial Maturity Assessment can access the tool here.
Upon completion of the assessment, sponsors will receive an evaluation relative to their peers, with all competitor data remaining anonymous. In addition, all participants will receive a report based on responses, which can be used to document current disclosure maturity and assess opportunities for improvement.
“The Clinical Trial Disclosure Maturity Assessment has provided valuable insight into current disclosing practices and emerging trends,” states TrialScope Chief Strategy Officer and Assessment Author Thomas Wicks, “Using this tool, we have been able to identify shifts in disclosure focus, scope and capabilities and reflect them back to participating clinical trial sponsors for benchmarking purposes. The results help sponsors gauge their own performance and take advantage of their strengths while developing plans to address any gaps in their practices.”
Over 50 clinical trial sponsors participated in the first assessment in 2015 and the results were published in a white paper titled, “Clinical Trial Reporting Compliance: Self-Assessment Survey Results from Pharma, Biotech, and Academic Trial Sponsors.”
About TrialScopeTrialScope simplifies the complexities of clinical trial transparency. TrialScope’s award-winning, proven solutions have been implemented successfully and rigorously tested in the most complex environments and are managing disclosures for sponsors that are responsible for over 35% of industry sponsored clinical trials posted on clincialtrials.gov. The company’s market-driven solutions and expertise enable sponsors to improve performance, mitigate compliance risk, and ultimately optimize efficiencies with clinical content lifecycle management tools, expertise and processes. TrialScope technologies are offered via a validation-ready SaaS platform hosted in a private cloud.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
